Pharmaceutical - Respiratory and Pulmonary

Filter

Current filters:

Respiratory and Pulmonary

Popular Filters

26 to 50 of 317 results

Boehringer Ingelheim invests 100 million euros to expanded Respimat production, as it's launched in UK

Boehringer Ingelheim invests 100 million euros to expanded Respimat production, as it's launched in UK

01-10-2014

German family-owned pharma major Boehringer Ingelheim is investing more than 100 million euros ($127…

Boehringer IngelheimGermanyMarkets & MarketingPharmaceuticalProductionRespimatRespiratory and PulmonarySpiriva RespimatUK

Sanofi and Regeneron's dupilumab meets all primary and secondary endpoints Phase IIa study

Sanofi and Regeneron's dupilumab meets all primary and secondary endpoints Phase IIa study

01-10-2014

French drug major Sanofi and US biotech company Regeneron's dupilumab has met all primary and secondary…

dupilumabFrancePharmaceuticalRegeneronResearchRespiratory and PulmonarySanofiUSA

Merck's entry into allergic rhinitis market will send total market value soaring by 2018, says GlobalData

Merck's entry into allergic rhinitis market will send total market value soaring by 2018, says GlobalData

30-09-2014

The US market for treatments of allergic rhinitis is set to see its value increase fourfold by 2018,…

GlobalDataGrastekMarkets & MarketingMerck & CoOralairPharmaceuticalRagwitekRespiratory and PulmonarySingulairUSA

Verona Pharma appoints Biresh Roy as chief financial officer

Verona Pharma appoints Biresh Roy as chief financial officer

30-09-2014

UK respiratory specialist Verona Pharma has appointed Biresh Roy as chief financial officer and member…

BoardroomPharmaceuticalRespiratory and PulmonaryUKVerona Pharma

Almirall’s aclidinium bromide/formoterol backed by EMA/CHMP to treat COPD

Almirall’s aclidinium bromide/formoterol backed by EMA/CHMP to treat COPD

26-09-2014

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a…

aclidiniumAlmirallAstraZenecaBrimica GenuairDuaklir GenuairEuropeformoterolPharmaceuticalRegulationRespiratory and Pulmonary

Asthma’s treatment pipeline very strong as more personalized medicines emerge

Asthma’s treatment pipeline very strong as more personalized medicines emerge

26-09-2014

Asthma has a very strong drug pipeline, with almost 100 novel molecules or formulations currently in…

AstraZenecabenralizumabBosatriaCinquilGlaxoSmithKlineGlobalPharmaceuticalResearchRespiratory and PulmonaryTeva Pharmaceutical Industries

Boehringer’s Spiriva Respimat OKed by FDA for maintenance treatment of COPD

Boehringer’s Spiriva Respimat OKed by FDA for maintenance treatment of COPD

25-09-2014

German family-owned pharma major Boehringer Ingelheim Pharmaceuticals has received US Food and Drug Administration…

Boehringer IngelheimPharmaceuticalRegulationRespiratory and PulmonarySpirivaUSA

Allergy Therapeutics shows increase in revenue in preliminary results

Allergy Therapeutics shows increase in revenue in preliminary results

22-09-2014

UK-based Allergy Therapeutics has announced its preliminary results for the year ended June 30, 2014,…

Allergy TherapeuticsFinancialPharmaceuticalPollinex QuattroRespiratory and PulmonaryUK

FDA accepts Tuzistra XR NDA for full review

FDA accepts Tuzistra XR NDA for full review

15-09-2014

The US Food and Drug Administration has confirmed that the New Drug Application for Tuzistra XR, a prescription…

LicensingPharmaceuticalRegulationRespiratory and PulmonaryTris PharmaTuzistraUSAVernalis

Ario Pharma acquires PharmEste’s TRPA1 research assets

11-09-2014

Cambridge, UK-based biopharma company Ario Pharma says it has acquired the TRPA1 antagonist research…

Ario PharmaInflammatory diseasesMergers & AcquisitionsPharmaceuticalPharmEsteRespiratory and Pulmonary

ERS 2014: Positive new data on Boehringer’s nintedanib in IPF patients

ERS 2014: Positive new data on Boehringer’s nintedanib in IPF patients

10-09-2014

A pre-specified subgroup analysis from the two replicate Phase III INPULSI trials, presented today at…

Boehringer IngelheimnintedanibPharmaceuticalResearchRespiratory and Pulmonary

Boehringer's tiotropium improves lung function in adolescent patients with symptomatic asthma

Boehringer's tiotropium improves lung function in adolescent patients with symptomatic asthma

09-09-2014

German family-owned drug major Boehringer Ingelheim has reported Phase III trial results showing that…

AsthmaBoehringer IngelheimGermanyMajorPharmaceuticalPulmonologyResearchRespiratory and Pulmonarytiotropium

ERS 2014: GSK reports positive Phase III results of its mepolizumab in asthma

ERS 2014: GSK reports positive Phase III results of its mepolizumab in asthma

08-09-2014

UK pharma major GlaxoSmithKline has reported positive data from its Phase III asthma studies of mepolizumab,…

GlaxoSmithKlineGSKImmunosuppressantsmepolizumabMepolizumabPharmaceuticalResearchRespiratory and PulmonaryUK

ERS 2014: Mundipharma reports positive Ph III results for flutiform in pediatric asthma

ERS 2014: Mundipharma reports positive Ph III results for flutiform in pediatric asthma

08-09-2014

UK inhalation drug delivery specialist Skyepharma today announced that data from a randomized, multicenter,…

FlutiformGermanyMundipharmaPharmaceuticalPulmonologyResearchRespiratory and PulmonaryRespiratory therapySkyepharmaUK

ALK's strategic partner Torii in final stage of clinical development for Japanese cedar allergy

ALK's strategic partner Torii in final stage of clinical development for Japanese cedar allergy

02-09-2014

Japanese drugmaker Torii Pharmaceutical has begun a Phase II/III development program with Denmark-based…

ALK AbelloAllergologyImmunologyJapanMedicinePharmaceuticalResearchRespiratory and PulmonarySLIT-tabletTorii Pharma

Roche makes another acquisition, paying $8.3 billion for InterMune

Roche makes another acquisition, paying $8.3 billion for InterMune

25-08-2014

Announcing its fourth acquisition this year, Swiss pharma major Roche said on Sunday that it has entered…

EsbrietInterMuneMergers & AcquisitionsPharmaceuticalRespiratory and PulmonaryRoche

Asthma agents currently face a suboptimal coverage environment in Brazil and Mexico

Asthma agents currently face a suboptimal coverage environment in Brazil and Mexico

21-08-2014

The asthma market in Brazil and Mexico currently faces severe coverage restrictions and, as the treatment…

Boehringer IngelheimBrazilGenentechMexicoNovartisPfizerPharmaceuticalRespiratory and PulmonarySpirivaXolair

US FDA backs approval of GSK’s Arnuity Ellipta for asthma

US FDA backs approval of GSK’s Arnuity Ellipta for asthma

21-08-2014

UK pharma giant GlaxoSmithKline revealed late yesterday that the US Food and Drug Administration has…

Arnuity ElliptaGlaxoSmithKlinePharmaceuticalRegulationRespiratory and PulmonaryUSA

FDA panel recommends Boehringer drug for the maintenance treatment of COPD

FDA panel recommends Boehringer drug for the maintenance treatment of COPD

15-08-2014

There was good news late yesterday for German family-owned pharma major Boehringer Ingelheim, when an…

Boehringer IngelheimPharmaceuticalRegulationRespiratory and PulmonarySpirivatiotropiumUS Food and Drug AdministrationUSA

China’s ZAI Lab in-licenses two respiratory drugs from Sanofi

China’s ZAI Lab in-licenses two respiratory drugs from Sanofi

14-08-2014

China-based ZAI Lab has obtained global rights for two novel compounds from French pharma major Sanofi,…

Chronic lower respiratory diseasesGlobalLicensingPharmaceuticalRespiratory and PulmonarySanofiZAI Lab

ALK Abello reports strong improvement in 2nd-qtr financials

ALK Abello reports strong improvement in 2nd-qtr financials

13-08-2014

Denmark-based allergy specialist ALK Abello has reported significant progress in its sales for the second…

ALK AbelloDenmarkFinanceFinancialNorwegian kronePharmaceuticalRespiratory and Pulmonary

Medivir licenses RSV program from Boehringer Ingelheim

Medivir licenses RSV program from Boehringer Ingelheim

05-08-2014

Swedish drugmaker Medivir has entered a license agreement with German family-owned pharma major Boehringer…

Boehringer IngelheimGlobalHuman respiratory syncytial virusLicensingMedivirMononegaviralesPharmaceuticalRespiratory and PulmonaryViral diseases

26 to 50 of 317 results

Back to top